UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
________________
FORM
8-K
________________
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): February
22, 2005
ATHEROGENICS,
INC.
(Exact
Name of Registrant as Specified in its Charter)
|
Georgia |
0-31261 |
58-2108232 |
|
(State
or other jurisdiction |
(Commission |
(I.R.S.
Employer |
|
of
incorporation) |
File
Number) |
Identification
Number) |
8995
Westside Parkway
Alpharetta,
GA 30004
(Address
of principal executive offices)
Registrant's
telephone number, including area code (678)
336-2500
_________________
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other Events.
On
February 22, 2005, AtheroGenics, Inc. issued a press release to announce that
the U.S. Food and Drug Administration has approved its proposed amendment to the
ARISE Phase III clinical trial protocol for AGI-1067. A copy of the press
release is attached to this current report on Form 8-K as Exhibit
99.1.
Item
9.01 Financial Statements and Exhibits.
The
following exhibit is attached to this current report on Form 8-K as Exhibit
99.1.
|
Exhibit
No. |
|
Description |
| |
|
|
|
99.1 |
- |
Press
Release dated February 22, 2005 |
| |
|
|
____________________
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
| |
|
ATHEROGENICS,
INC. |
| |
|
|
|
Date:
February 22, 2005 |
|
By:
MARK P. COLONNESE |
| |
|
Mark
P. Colonnese |
| |
|
Senior
Vice President of Finance and |
| |
|
Administration and Chief Financial Officer |
____________________
EXHIBIT
INDEX
|
Exhibit
No. |
|
Description |
| |
|
|
|
99.1 |
- |
Press
Release dated February 22, 2005 |
| |
|
|